EVAXION BIOTECH A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 USD | +4.80% |
|
-8.39% | -58.58% |
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.84
USD
Average target price
11.75
USD
Spread / Average Target
+313.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.58% | 15.37M | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +36.33% | 38.48B | |
| +12.62% | 26.36B | |
| -12.11% | 26.22B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- EVAX Stock
- News Evaxion Biotech A/S
- European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading
